Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Schultheis, B.
Reuter, D.
Ebert, M. P.
Siveke, J.
Kerkhoff, A.
Berdel, W. E.
Hofheinz, R.
Behringer, D. M.
Schmidt, W. E.
Goker, E.
De Dosso, S.
Kneba, M.
Yalcin, S.
Overkamp, F.
Schlegel, F.
Dommach, M.
Rohrberg, R.
Steinmetz, T.
Bulitta, M.
Strumberg, D.

January 2017

WOS: 000411827200016PubMed ID: 28961832Background: This randomized study was designed to investigate...

Open Access Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Purpose

August 2016

The purpose of this study is to retrospectively compare the efficacy and tolerability between three ...

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer. Preliminary results.

Chauffert, B.
Toledano, A.
Bonnetain, Franck
Triboulet, Jp
Bouche, O.
Rougier, P.
Bosset, Jf.
Aparicio, T.
Masskouri, F.
Bedenne, L.

June 2006

International audienceBackground: The GITSG studies have shown a greater survival after 5 FU-based c...

Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer

Hideki Ueno
Tatsuya Ioka
Masafumi Ikeda
Shinichi Ohkawa
Hiroaki Yanagimoto
Narikazu Boku
Akira Fukutomi
Kazuya Sugimori
Hideo Baba
Kenji Yamao
Tomotaka Shimamura
Masayuki Sho
Masayuki Kitano
Ann-lii Cheng
Kazuhiro Mizumoto
Jen-shi Chen
Junji Furuse
Akihiro Funakoshi
Takashi Hatori
Taketo Yamaguchi
Shinichi Egawa
Atsushi Sato
Yasuo Ohashi
Takuji Okusaka

October 2016

See accompanying editorial on page 1621 Author affiliations appear at the end of this article. Publi...

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Ueno, Hideki
鄭安理

February 2014

Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and...

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

Cunningham, David
Chau, Ian
Stocken, Deborah D.
Valle, Juan W.
Smith, David
Steward, William
Harper, Peter G.
Dunn, Janet
Tudur-Smith, Catrin
West, Julia
Falk, Stephen
Crellin, Adrian
Adab, Fawzi
Thompson, Joyce
Leonard, Pauline
Ostrowski, Joe
Eatock, Martin
Scheithauer, Werner
Herrmann, Richard
Neoptolemos, John P.

January 2009

PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic...

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

COLUCCI G.
LABIANCA R.
DI COSTANZO F.
GEBBIA V.
CARTENÌ G.
MASSIDDA B.
DAPRETTO E.
MANZIONE L.
PIAZZA E.
SANNICOLÒ M.
CIAPARRONE M.
CAVANNA L.
GIULIANI F.
MAIELLO E.
TESTA A.
PEDERZOLI P.
FALCONI V.
DI MAIO M.
PERRONE F.
GALLO, Ciro

January 2010

Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer...

Gemcitabine Compared With G Combination Therapy in Advanc A Systematic Review and M

Zhuofei Bi

August 2016

Abstract: Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to ...

Annals of Oncology

H. Oettle
D. Richards
R. K. Ramanathan
J. L. Van Laethem
M. Peeters
M. Fuchs
A. Zimmermann
W. John
D. Von Hoff
M. Arning
H. L. Kindler

March 2015

doi:10.1093/annonc/mdi309Original article A phase III trial of pemetrexed plus gemcitabine versus ge...

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann, R.
Bodoky, G.
Ruhstaller, T.
Glimelius, B.
Bajetta, E.
Schüller, J.
Saletti, P.
Bauer, J.
Figer, A.
Pestalozzi, B.
Köhne, C.H.
Mingrone, W.
Stemmer, S.M.
Tàmas, K.
Kornek, G.V.
Koeberle, D.
Cina, S.
Bernhard, J.
Dietrich, D.
Scheithauer, W.

January 2007

PURPOSE: This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabin...

Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study

Yildiz, R.
Uncu, D.
Ozdemir, N.
Goksel, G.
Harputoglu, H.
Gumus, M.
Buyukberber, S.
Kucukoner, M.
Durnali, A. G.
Kaplan, M. A.
Balakan, O.
Dane, F.
Geredeli, C.
Ozkan, M.
Helvaci, K.
ELKIRAN, EMİN TAMER
Colak, D.
Dikiltas, M.
Algin, E.
Kos, F. T.
Inal, A.
Benekli, M.
ÜNEK, İLKAY TUĞBA
Isikdogan, A.

January 2012

The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II ...

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

Van Laethem, Jean*-Luc
Hammel, Pascal
Mornex, Francoise
Azria, David
Van Tienhoven, Geertjan
Vergauwe, Philippe
Peeters, Marc
Polus, Marc
Praet, Michel
Mauer, Murielle
Collette, Laurence
Budach, Volker
Lutz, Manfred
Van Cutsem, Eric
Haustermans, Karin

January 2010

PURPOSE: The role of adjuvant chemoradiotherapy (CRT) in resectable pancreatic cancer is still debat...

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Herrmann, R
Bodoky, G
Ruhstaller, T
Glimelius, B
Bajetta, E
Schüller, J
Saletti, P
Bauer, J
Figer, A
Pestalozzi, B
Köhne, CH
Mingrone, W
Stemmer, SM
Tàmas, K
Kornek, GV
Koeberle, D
Cina, S
Bernhard, J
Dietrich, D
Scheithauer, W
Swiss, Group for Clinical Cancer Research
Central, European Cooperative Oncology Group

January 2007

This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap...

Clinical Trial Note Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)

Atsuyuki Maeda
Narikazu Boku
Akira Fukutomi
Satoshi Kondo
Taira Kinoshita
Masato Nagino
Katsuhiko Uesaka

January 2007

A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous...

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

O'Neil, B.H.
Scott, A.J.
Ma, W.W.
Cohen, S.J.
Leichman, L.
Aisner, D.L.
Menter, A.R.
Tejani, M.A.
Cho, J.K.
Granfortuna, J.
Coveler, L.
Olowokure, O.O.
Baranda, J.C.
Cusnir, M.
Phillip, P.
Boles, J.
Nazemzadeh, R.
Rarick, M.
Cohen, D.J.
Radford, J.
Fehrenbacher, L.
Bajaj, R.
Bathini, V.
Fanta, P.
Berlin, J.
McRee, A.J.
Maguire, R.
Wilhelm, F.
Maniar, M.
Jimeno, A.
Gomes, C.L.
Messersmith, W.A.

September 2015

BACKGROUND: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor o...

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Schultheis, B.
Reuter, D.
Ebert, M. P.
Siveke, J.
Kerkhoff, A.
Berdel, W. E.
Hofheinz, R.
Behringer, D. M.
Schmidt, W. E.
Goker, E.
De Dosso, S.
Kneba, M.
Yalcin, S.
Overkamp, F.
Schlegel, F.
Dommach, M.
Rohrberg, R.
Steinmetz, T.
Bulitta, M.
Strumberg, D.

January 2017

WOS: 000411827200016PubMed ID: 28961832Background: This randomized study was designed to investigate...

Open Access Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Purpose

August 2016

The purpose of this study is to retrospectively compare the efficacy and tolerability between three ...

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer. Preliminary results.

Chauffert, B.
Toledano, A.
Bonnetain, Franck
Triboulet, Jp
Bouche, O.
Rougier, P.
Bosset, Jf.
Aparicio, T.
Masskouri, F.
Bedenne, L.

June 2006

International audienceBackground: The GITSG studies have shown a greater survival after 5 FU-based c...

Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer

Hideki Ueno
Tatsuya Ioka
Masafumi Ikeda
Shinichi Ohkawa
Hiroaki Yanagimoto
Narikazu Boku
Akira Fukutomi
Kazuya Sugimori
Hideo Baba
Kenji Yamao
Tomotaka Shimamura
Masayuki Sho
Masayuki Kitano
Ann-lii Cheng
Kazuhiro Mizumoto
Jen-shi Chen
Junji Furuse
Akihiro Funakoshi
Takashi Hatori
Taketo Yamaguchi
Shinichi Egawa
Atsushi Sato
Yasuo Ohashi
Takuji Okusaka

October 2016

See accompanying editorial on page 1621 Author affiliations appear at the end of this article. Publi...

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Ueno, Hideki
鄭安理

February 2014

Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and...

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

Cunningham, David
Chau, Ian
Stocken, Deborah D.
Valle, Juan W.
Smith, David
Steward, William
Harper, Peter G.
Dunn, Janet
Tudur-Smith, Catrin
West, Julia
Falk, Stephen
Crellin, Adrian
Adab, Fawzi
Thompson, Joyce
Leonard, Pauline
Ostrowski, Joe
Eatock, Martin
Scheithauer, Werner
Herrmann, Richard
Neoptolemos, John P.

January 2009

PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic...

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

COLUCCI G.
LABIANCA R.
DI COSTANZO F.
GEBBIA V.
CARTENÌ G.
MASSIDDA B.
DAPRETTO E.
MANZIONE L.
PIAZZA E.
SANNICOLÒ M.
CIAPARRONE M.
CAVANNA L.
GIULIANI F.
MAIELLO E.
TESTA A.
PEDERZOLI P.
FALCONI V.
DI MAIO M.
PERRONE F.
GALLO, Ciro

January 2010

Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer...

Gemcitabine Compared With G Combination Therapy in Advanc A Systematic Review and M

Zhuofei Bi

August 2016

Abstract: Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to ...

Annals of Oncology

H. Oettle
D. Richards
R. K. Ramanathan
J. L. Van Laethem
M. Peeters
M. Fuchs
A. Zimmermann
W. John
D. Von Hoff
M. Arning
H. L. Kindler

March 2015

doi:10.1093/annonc/mdi309Original article A phase III trial of pemetrexed plus gemcitabine versus ge...

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann, R.
Bodoky, G.
Ruhstaller, T.
Glimelius, B.
Bajetta, E.
Schüller, J.
Saletti, P.
Bauer, J.
Figer, A.
Pestalozzi, B.
Köhne, C.H.
Mingrone, W.
Stemmer, S.M.
Tàmas, K.
Kornek, G.V.
Koeberle, D.
Cina, S.
Bernhard, J.
Dietrich, D.
Scheithauer, W.

January 2007

PURPOSE: This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabin...

Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study

Yildiz, R.
Uncu, D.
Ozdemir, N.
Goksel, G.
Harputoglu, H.
Gumus, M.
Buyukberber, S.
Kucukoner, M.
Durnali, A. G.
Kaplan, M. A.
Balakan, O.
Dane, F.
Geredeli, C.
Ozkan, M.
Helvaci, K.
ELKIRAN, EMİN TAMER
Colak, D.
Dikiltas, M.
Algin, E.
Kos, F. T.
Inal, A.
Benekli, M.
ÜNEK, İLKAY TUĞBA
Isikdogan, A.

January 2012

The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II ...

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

Van Laethem, Jean*-Luc
Hammel, Pascal
Mornex, Francoise
Azria, David
Van Tienhoven, Geertjan
Vergauwe, Philippe
Peeters, Marc
Polus, Marc
Praet, Michel
Mauer, Murielle
Collette, Laurence
Budach, Volker
Lutz, Manfred
Van Cutsem, Eric
Haustermans, Karin

January 2010

PURPOSE: The role of adjuvant chemoradiotherapy (CRT) in resectable pancreatic cancer is still debat...

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Herrmann, R
Bodoky, G
Ruhstaller, T
Glimelius, B
Bajetta, E
Schüller, J
Saletti, P
Bauer, J
Figer, A
Pestalozzi, B
Köhne, CH
Mingrone, W
Stemmer, SM
Tàmas, K
Kornek, GV
Koeberle, D
Cina, S
Bernhard, J
Dietrich, D
Scheithauer, W
Swiss, Group for Clinical Cancer Research
Central, European Cooperative Oncology Group

January 2007

This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap...

Clinical Trial Note Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)

Atsuyuki Maeda
Narikazu Boku
Akira Fukutomi
Satoshi Kondo
Taira Kinoshita
Masato Nagino
Katsuhiko Uesaka

January 2007

A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous...

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

O'Neil, B.H.
Scott, A.J.
Ma, W.W.
Cohen, S.J.
Leichman, L.
Aisner, D.L.
Menter, A.R.
Tejani, M.A.
Cho, J.K.
Granfortuna, J.
Coveler, L.
Olowokure, O.O.
Baranda, J.C.
Cusnir, M.
Phillip, P.
Boles, J.
Nazemzadeh, R.
Rarick, M.
Cohen, D.J.
Radford, J.
Fehrenbacher, L.
Bajaj, R.
Bathini, V.
Fanta, P.
Berlin, J.
McRee, A.J.
Maguire, R.
Wilhelm, F.
Maniar, M.
Jimeno, A.
Gomes, C.L.
Messersmith, W.A.

September 2015

BACKGROUND: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor o...

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Schultheis, B.
Reuter, D.
Ebert, M. P.
Siveke, J.
Kerkhoff, A.
Berdel, W. E.
Hofheinz, R.
Behringer, D. M.
Schmidt, W. E.
Goker, E.
De Dosso, S.
Kneba, M.
Yalcin, S.
Overkamp, F.
Schlegel, F.
Dommach, M.
Rohrberg, R.
Steinmetz, T.
Bulitta, M.
Strumberg, D.

January 2017

WOS: 000411827200016PubMed ID: 28961832Background: This randomized study was designed to investigate...

Open Access Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Purpose

August 2016

The purpose of this study is to retrospectively compare the efficacy and tolerability between three ...

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer. Preliminary results.

Chauffert, B.
Toledano, A.
Bonnetain, Franck
Triboulet, Jp
Bouche, O.
Rougier, P.
Bosset, Jf.
Aparicio, T.
Masskouri, F.
Bedenne, L.

June 2006

International audienceBackground: The GITSG studies have shown a greater survival after 5 FU-based c...

Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer

Abstract

Extracted data

Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer

Abstract

Extracted data

Related items

Related items